PureTech Health (LON:PRTC) Shares Cross Above 50 Day Moving Average – Should You Sell?

PureTech Health plc (LON:PRTC) shares passed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of GBX 120.79 and traded as high as GBX 127. PureTech Health shares last traded at GBX 112.30, with a volume of 2,277,844 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reiterated a “buy” rating and set a GBX 508 target price on shares of PureTech Health in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, PureTech Health presently has a consensus rating of “Buy” and an average price target of GBX 508.

PureTech Health Trading Up 0.9%

The firm has a market capitalization of £286.86 million, a price-to-earnings ratio of -2.54 and a beta of 0.77. The business’s 50 day moving average price is GBX 120.44 and its 200-day moving average price is GBX 123.93. The company has a debt-to-equity ratio of 4.78, a current ratio of 4.60 and a quick ratio of 2.51.

Insider Activity at PureTech Health

In other news, insider John LaMattina purchased 93,944 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were acquired at an average price of GBX 1 per share, with a total value of £939.44. Also, insider Michele Holcomb purchased 93,944 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was purchased at an average price of GBX 1 per share, for a total transaction of £939.44. In the last 90 days, insiders acquired 617,569 shares of company stock worth $18,063,751. 13.41% of the stock is currently owned by company insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.